EMA Authorised: Verzenios (abemaciclib) — Eli Lilly Nederland B.V.

View source ↗

Summary

The EMA authorised Verzenios (abemaciclib) under Eli Lilly Nederland B.V. for use in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Verzenios (abemaciclib)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Eli Lilly Nederland B.V.. Decision date: 29/01/2026